Daniel Tillett is a biotech entrepreneur and software CEO leading Race Oncology as Managing Director and serving as CEO and Founder of Nucleics, the company behind PeakTrace and related DNA sequencing tools. He combines deep biochemical training with software-led biology, holding a PhD in Biochemistry and Molecular Biology from UNSW and a BS in Biochemistry (Honours 1). Over more than two decades, he has steered ventures across biotech and software, from founding Nucleics in 1999 to shaping Race Oncology’s scientific and strategic direction as CSO before moving into top executive roles. He also contributes to the broader startup ecosystem as a board member and investor for biotech and tech firms, including SmartrMail, Simble Solutions, Tryp Therapeutics, and active angel investments with Sydney Angels. Based in the Greater Sydney Area, he operates at the intersection of research, product development, and corporate governance, orchestrating cross-functional teams to translate complex biology into scalable technologies. His work is marked by a rare blend of scientific depth and entrepreneurial grit, enabling him to turn ambitious life sciences ideas into practical, growth-oriented companies.
Contributions:7 commits, 1 PR, 3 pushes in 3 years 4 months
englishspellingreformbrowser
Find and Hire Top DevelopersWe’ve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.